Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?
Alkermes $ALKS has one shot at making ALKS-3831 a standout in the schizophrenia field. For years now, investigators expected to be able to show that the drug performs pretty much the same as the generic olanzapine in terms of efficacy, but significantly better in terms of preventing the weight gain — and all the risks that come with it — that afflicts patients on the old drug.
But in the first of two Phase III readouts on Thursday evening, investigators were only able to point to a similar efficacy with olanzapine without the benefit on weight gain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.